Answer up front: these three research peptides differ by receptor class. Semaglutide is a single GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP agonist — it adds the GIP receptor on top of GLP-1; and retatrutide is a triple GLP-1/GIP/glucagon agonist — it adds the glucagon receptor as well. That single → dual → triple agonist progression, one added receptor at each step, is the framework this comparison uses, framed strictly as receptor pharmacology and third-party research literature rather than human use.
Why This Comparison Matters
Semaglutide, tirzepatide, and retatrutide are the three incretin-mimetic research peptides most frequently requested by Canadian laboratories studying metabolic pathway biology. Each targets an overlapping but distinct combination of receptors, which makes them useful as a comparative panel for receptor pharmacology and adipose/hepatic metabolism research designs. This guide summarizes the structural and mechanistic differences relevant to protocol design — it does not describe or endorse human use of any compound.
None of the three peptides discussed here are approved by Health Canada, the FDA, or any regulatory body for human or veterinary therapeutic use. All are sold by Lux BioPure exclusively as research chemicals for in vitro and preclinical laboratory use.
Receptor Targets at a Glance
| Compound | Receptor Targets | Sequence Length | Molecular Weight | HPLC Purity |
|---|---|---|---|---|
| Semaglutide | GLP-1 (mono-agonist) | 31 aa | ~4114 Da | 99.1% |
| Tirzepatide | GLP-1 + GIP (dual agonist) | 39 aa | ~4813 Da | 99.2% |
| Retatrutide | GLP-1 + GIP + Glucagon (triple agonist) | 39 aa | ~4816 Da | 99.4% |
Each compound is a fatty-acid-modified peptide engineered for extended albumin-binding half-life, distinguishing this class from smaller unmodified research peptides like BPC-157. The formulas and CAS numbers for each Lux BioPure lot are listed on the respective product page and confirmed against batch-specific certificates of analysis on /lab-reports.
What Is a Dual Agonist? GLP-1 vs GIP vs Glucagon
In receptor pharmacology an agonist is a molecule that binds a receptor and switches it on. A single (mono) agonist engages one receptor; a dual agonist — also written "double agonist" — is a single molecule engineered to activate two receptors at once; a triple agonist (tri-agonist) activates three. This incretin research class maps cleanly onto that ladder:
- Single GLP-1 agonist — semaglutide. Targets only the glucagon-like peptide-1 (GLP-1) receptor. This is the most mature and most-cited receptor pharmacology of the three, which is why it serves as the baseline arm in comparative designs.
- Dual GLP-1/GIP agonist — tirzepatide. Adds the glucose-dependent insulinotropic polypeptide (GIP) receptor to GLP-1. It is the reference dual agonist (or double agonist) in the incretin literature, and the reason researchers ask whether co-activating the GIP receptor produces additive or synergistic receptor signaling relative to GLP-1 alone.
- Triple GLP-1/GIP/glucagon agonist — retatrutide. Adds the glucagon receptor on top of the GLP-1/GIP pair, making it a triple agonist. Glucagon receptor agonism is the pharmacologically distinct third pathway, associated in the published literature with hepatic fatty-acid oxidation and energy-expenditure signaling.
None of this describes an outcome a buyer should expect — it is a map of which receptors each molecule engages, drawn from receptor pharmacology and third-party trial literature. Which GIP receptor agonist, dual agonist, or triple agonist a laboratory selects depends entirely on which pathway a given study is isolating.
Mechanistic Differences
Semaglutide is a GLP-1 receptor mono-agonist. Its research literature is the most mature of the three: GLP-1 receptor agonism at the pancreatic beta cell drives glucose-dependent insulin secretion, slows gastric emptying, and modulates hypothalamic appetite signaling. As the "first generation" compound in this class, semaglutide is a common baseline in comparative incretin studies.
Tirzepatide adds GIP receptor agonism on top of the GLP-1 mechanism. GIP receptor activity at the adipocyte level appears to influence lipolysis regulation and fat storage dynamics, and researchers investigating whether dual-incretin agonism produces additive or synergistic effects relative to GLP-1 alone frequently use tirzepatide as the comparator arm.
Retatrutide goes a step further, adding glucagon receptor agonism to the GLP-1/GIP combination. Glucagon receptor activation increases hepatic fatty acid oxidation and resting energy expenditure — a pharmacologically distinct feature not present in the other two. This third receptor pathway is the reason retatrutide is structurally and mechanistically the most complex of the three, and why its synthesis (and pricing) reflects that complexity.
Published Clinical Trial Literature (Third-Party Research Context)
> The following table summarizes third-party human clinical trial data conducted by each drug's respective developer under regulatory oversight, reported here strictly for scientific and educational context. It is not a claim about, or representative of, any research chemical sold by Lux BioPure.
| Compound | Trial Duration | Reported Endpoint (per publication) |
|---|---|---|
| Semaglutide | 68 weeks | ~15% |
| Tirzepatide | 72 weeks | ~20.9% |
| Retatrutide | 48 weeks | ~24% |
These trials differ in duration, dosing protocol, and population, so the figures are not directly comparable as a ranking — the varying timepoints (48 vs. 68 vs. 72 weeks) are a methodological caveat researchers should account for when citing this literature. All figures describe the published trial record for investigational or since-approved drug products, not outcomes attributable to any research peptide sold for in vitro use.
Half-Life and Dosing Frequency in Published Protocols
All three compounds carry a fatty acid side chain that extends circulating half-life via albumin binding, enabling once-weekly administration in the clinical trial protocols from which this data derives:
- Semaglutide: approximately 1 week half-life
- Tirzepatide: approximately 5 days half-life
- Retatrutide: approximately 6 days half-life
For in vitro research design, half-life data informs incubation timing and repeated-dose cell culture protocols rather than any administration schedule.
Research Applications by Compound
Semaglutide is most often selected for baseline GLP-1 receptor characterization studies, comparative pharmacology designs establishing a reference point, and reproducing the largest existing body of receptor-binding literature.
Tirzepatide is selected when the research question specifically concerns the marginal contribution of GIP co-agonism — for example, adipocyte differentiation assays or comparative incretin signaling cascades where isolating the GIP receptor's role from GLP-1 is the objective.
Retatrutide is selected for research designs examining glucagon receptor contributions to hepatic lipid metabolism, or for balanced tri-agonist receptor-binding characterization where all three pathways need representation in a single molecule.
Quality Verification Considerations
Because all three peptides share the fatty-acid-modification synthesis pathway, quality verification carries the same considerations across the class:
- HPLC purity ≥98% is the research-grade minimum; Lux BioPure's current batches report 99.1–99.4% across this trio
- Mass spectrometry confirmation of observed vs. theoretical molecular weight is essential — the fatty acid modification creates more opportunities for synthesis error than in smaller unmodified peptides
- Batch-specific documentation, not generic manufacturer certificates
- Independent third-party laboratory verification is strongly recommended for compounds of this structural complexity
Semaglutide, tirzepatide, and retatrutide are among the priority SKUs Lux BioPure is testing with independent Janoshik HPLC and mass-spec analysis; batch results and PDFs are published as they clear as they become available at /lab-reports. Read how to interpret a peptide COA before reviewing any batch data.
Reconstitution Notes for This Compound Class
All three are larger fatty-acid-modified peptides that benefit from careful reconstitution: add bacteriostatic water slowly along the vial wall and swirl gently rather than shaking, which can cause aggregation. Work out target concentrations for each compound with the reconstitution dose calculator before adding diluent, then see the full reconstitution guide for step-by-step handling and the storage guide for post-reconstitution stability windows.
Choosing Between the Three for a Research Design
There is no universally "better" compound among the three — the correct choice depends entirely on which receptor pathway (or combination) the research question is targeting:
- Testing a single GLP-1 pathway in isolation → semaglutide
- Testing GLP-1 + GIP co-agonism → tirzepatide
- Testing the full three-receptor incretin/glucagon panel → retatrutide
Many comparative study designs use two or all three side by side specifically to isolate the marginal contribution of each additional receptor target, which is why Canadian laboratories frequently order more than one of these compounds together. Learn more about each compound's individual pharmacology in the Pepidia entries for semaglutide, tirzepatide, and retatrutide.
Pricing and Availability (CAD)
All three compounds are currently in stock at Lux BioPure as 10 mg single vials, with 10-packs available for laboratories running larger comparative studies:
| Compound | Single Vial | 10-Pack |
|---|---|---|
| Semaglutide 10mg | $80 | $640 |
| Tirzepatide 10mg | $60 | $480 |
| Retatrutide 10mg | $90 | $720 |
Pricing reflects synthesis complexity — retatrutide's three-receptor design and additional purification steps place it at a modest premium over the simpler mono- and dual-agonist molecules. All three ship domestically from Canadian inventory via Canada Post Xpresspost, avoiding the customs delays and brokerage fees that come with cross-border research chemical shipments.
Frequently Asked Questions
What is a dual agonist peptide? A dual agonist (also called a double agonist) is a single peptide engineered to activate two receptors at once. Tirzepatide is the archetype — it engages both the GLP-1 and the GIP incretin receptors, versus semaglutide, which is a single GLP-1 receptor agonist. The dual GLP-1/GIP design is studied for additive incretin signaling.
What is the difference between a dual and a triple agonist? A dual agonist activates two receptors; a triple agonist adds a third. Tirzepatide is a dual GLP-1/GIP agonist, while retatrutide is a triple GLP-1/GIP/glucagon agonist — the added glucagon receptor is what makes it a tri-agonist. Semaglutide, by contrast, is a single GLP-1 receptor agonist.
Which of these peptides are GIP receptor agonists? Both tirzepatide and retatrutide include GIP receptor agonism — tirzepatide as a dual GLP-1/GIP agonist and retatrutide as a triple GLP-1/GIP/glucagon agonist. Semaglutide does not target the GIP receptor; it is a GLP-1 receptor agonist only, which is why it anchors the single-agonist end of the class.
Is tirzepatide a double agonist or a dual agonist? "Dual agonist" and "double agonist" describe the same thing. Tirzepatide is a dual (double) agonist because it activates two receptors, GLP-1 and GIP. Retatrutide extends that to three receptors as a triple agonist, and semaglutide activates one — the GLP-1 receptor — as a single agonist.
Can these three compounds be studied together in the same protocol? Yes — many comparative incretin-biology designs specifically run all three side by side to isolate the marginal contribution of each additional receptor target (GIP, then glucagon) relative to the GLP-1-only baseline.
Which compound has the most published receptor-binding literature? Semaglutide, by a wide margin, since it has been in the clinical and academic literature the longest of the three.
Do purity standards differ between the three compounds? No — Lux BioPure applies the same ≥98% HPLC purity and mass-spec identity confirmation standard across all peptides in the catalog, though as larger, fatty-acid-modified molecules, these three carry additional synthesis complexity worth verifying against batch-specific documentation.
Is there a "strongest" compound among the three? That framing doesn't transfer meaningfully to in vitro receptor pharmacology — each compound's relevance depends entirely on which receptor pathway (or combination) a given research design is targeting, not a linear potency ranking.
Research Disclaimer
Semaglutide, tirzepatide, and retatrutide are not approved by Health Canada or any regulatory authority for human or veterinary therapeutic use. They are available exclusively for in vitro and preclinical laboratory research by qualified researchers. This content does not constitute medical advice and does not describe dosing for human or animal administration.